229 related articles for article (PubMed ID: 29383624)
1. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.
Ueda Y; Obara N; Yonemura Y; Noji H; Masuko M; Seki Y; Wada K; Matsuda T; Akiyama H; Ikezoe T; Chiba S; Kanda Y; Kawaguchi T; Shichishima T; Nakakuma H; Okamoto S; Nishimura JI; Kanakura Y; Ninomiya H
Int J Hematol; 2018 Jun; 107(6):656-665. PubMed ID: 29383624
[TBL] [Abstract][Full Text] [Related]
2. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Schrezenmeier H; Kulasekararaj A; Mitchell L; de Latour RP; Devos T; Okamoto S; Wells R; Popoff E; Cheung A; Wang A; Tomazos I; Patel Y; Lee JW
Ann Hematol; 2024 Jan; 103(1):5-15. PubMed ID: 37804344
[TBL] [Abstract][Full Text] [Related]
3. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
[TBL] [Abstract][Full Text] [Related]
4. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
5. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
6. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study.
Du Y; Yang Y; Yang C; Chen M; Han B
Hematology; 2022 Dec; 27(1):113-121. PubMed ID: 35068377
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
[TBL] [Abstract][Full Text] [Related]
10. Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
Hill A; Richards SJ; Rother RP; Hillmen P
Haematologica; 2007 Mar; 92(3):e31-3. PubMed ID: 17405753
[TBL] [Abstract][Full Text] [Related]
11. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
[TBL] [Abstract][Full Text] [Related]
13. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
Ninomiya H; Obara N; Chiba S; Usuki K; Nishiwaki K; Matsumura I; Shichishima T; Okamoto S; Nishimura JI; Ohyashiki K; Nakao S; Ando K; Kanda Y; Kawaguchi T; Nakakuma H; Harada D; Akiyama H; Kinoshita T; Ozawa K; Omine M; Kanakura Y
Int J Hematol; 2016 Nov; 104(5):548-558. PubMed ID: 27464489
[TBL] [Abstract][Full Text] [Related]
14. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
Füreder W; Sperr WR; Heibl S; Zebisch A; Pfeilstöcker M; Stefanzl G; Jäger E; Greiner G; Schwarzinger I; Kundi M; Keil F; Hoermann G; Bettelheim P; Valent P
Ann Hematol; 2020 Oct; 99(10):2303-2313. PubMed ID: 32856141
[TBL] [Abstract][Full Text] [Related]
16. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
17. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
18. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment.
DeZern AE; Jones RJ; Brodsky RA
Biol Blood Marrow Transplant; 2018 Dec; 24(12):e26-e30. PubMed ID: 30055352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
